Literature DB >> 220032

Inhibitory effects of long term treatment with a luteinizing hormone-releasing hormone agonist on the pituitary-gonadal axis in male and female rats.

L Cusan, C Auclair, A Belanger, L Ferland, P A Kelly, C Seguin, F Labrie.   

Abstract

Following previous observations of the potent antifertility effects of acute treatment with LHRH or its agonistic analogs in male and female rats, this study describes the effect of long term (up to 12 weeks) treatment with an LHRH agonist, [D-Ala6, des-Gly-NH210]LHRH ethylamide (LHRH-A), on testicular and ovarian gonadotropin receptor levels and function in the rat. Treatment of adult male rats with 100 ng LHRH-A every third day led to a progressive decrease of testis, seminal vesicle, and prostate weight up to 12 weeks of treatment, while the inhibitory effect (70%) on LH receptor levels was already maximal at 1 week. When adult female rats were injected daily with 5 microgram LHRH-A for 12 weeks, ovarian LH, FSH, and PRL receptor levels were reduced 50--90%, while plasma estradiol and progesterone levels were inhibited 60% (compared with diestrus day 1). The effect of chronic administration of a low dose (5 IU) of hCG in the male rat was transient. By contrast, no sign of resistance developed up to 12 weeks of treatment with the LHRH agonist in either male or female animals.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 220032     DOI: 10.1210/endo-104-5-1369

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

Review 1.  GnRH in pregnancy.

Authors:  J Gohar; M Mazor; J R Leiberman
Journal:  Arch Gynecol Obstet       Date:  1996       Impact factor: 2.344

2.  Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (Hoe-766) in young normal adult men.

Authors:  N Faure; F Labrie; A Belanger; A Lemay; J P Raynaud; M Von der Ohe; A T Fazekas
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

3.  Predominant suppression of follicle-stimulating hormone β-immunoreactivity after long-term treatment of intact and castrate adult male rats with the gonadotrophin-releasing hormone agonist deslorelin.

Authors:  A W Smith; C S Asa; B S Edwards; W J Murdoch; D C Skinner
Journal:  J Neuroendocrinol       Date:  2012-05       Impact factor: 3.627

4.  Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.

Authors:  S Li; C Lévesque; C S Geng; X Yan; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

5.  Direct inhibition of testicular function by gonadotropin-releasing hormone: mediation by specific gonadotropin-releasing hormone receptors in interstitial cells.

Authors:  R N Clayton; M Katikineni; V Chan; M L Dufau; K J Catt
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

6.  Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin.

Authors:  M G de Quijada; T W Redding; D H Coy; I Torres-Aleman; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

7.  Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.

Authors:  I Torres-Aleman; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

8.  Effect of chronic treatment with [D-Ala6, des-Gly-NH210]LHRH ethylamide on ovarian histology in the rat.

Authors:  C Séguin; G Pelletier; F Labrie
Journal:  Cell Tissue Res       Date:  1982       Impact factor: 5.249

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.